share_log

Blueprint Medicines | 8-K: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT ® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines | 8-K: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT ® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines | 8-K:Blueprint Medicinib 公布了强劲的2024年第一季度业绩,并上调了AYVAKIT® /AYVAKYT®(avapritinib)全年收入指引
美股sec公告 ·  05/02 07:13
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息